搜索结果

Search Results for " tumor-infiltrating "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T7776	ADH-503 GB1275	Complement System	Immunology/Inflammation
	ADH-503 (GB1275) 是一种可口服的变构CD11b 激动剂，可以导致与肿瘤相关的巨噬细胞重新极化，可减轻骨髓细胞的免疫抑制，并增强树突状细胞的反应。
T13379	(Z)-Leukadherin-1 ADH-503 free base	Complement System	Immunology/Inflammation
	(Z)-Leukadherin-1 (ADH-503 free base) 是 CD11b 的变构激动剂。
T26699	AZ10397767 AZ 10397767,AZ-10397767
	AZ10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). AZ10397767 significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor models.
T71890	F5446
	F5446 is a SUV39H1 inhibitor. F5446 has an EC50 of 0.496 μmol/L for SUV39H1 enzymatic activity. H3K9me3 was enriched in the promoters of GZMB, PRF1, FASLG, and IFNG in quiescent T cells. F5446 inhibited H3K9me3, thereby upregulating expression of these effectors in tumor-infiltrating CTLs and suppressing colon carcinoma growth in a CD8+ CTL-dependent manner in vivo. Our data indicate that SUV39H1 represses CTL effector gene expression and, in doing so, confers colon cancer immune escape.
T76410	Tyrosinase (206-214), human
	Tyrosinase(206-214), human (AFLPWHRLF)，一种由9个氨基酸组成的肽，为酪氨酸酶的表位。可被HLA-A24限制性肿瘤浸润淋巴细胞(TIL)识别的Tyrosinase(206-214), human，具有重要生物医学意义。
T79528	SWS1	PD-1/PD-L1	Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation
	SWS1为d-(+)-生物素缀合的PD-L1抑制剂(IC50: 1.8 nM)，显示出抗癌潜力。该化合物能提高肿瘤浸润淋巴细胞数量，并在B16-F10小鼠模型中展现抗肿瘤效果(TGI=66.1%)。
T77090	Mitazalimab
	Mitazalimab（ADC-1013; JNJ-64457107）是一种FcγR依赖性CD40激动剂，以肿瘤导向活性为特征。该化合物通过激活抗原呈递细胞（如树突状细胞[DC]），启动肿瘤反应性T细胞，进而诱导肿瘤特异性T细胞浸润并杀死肿瘤，有效重塑肿瘤浸润性骨髓微环境。
T70928	CB-1158-analog
	CB-1158-analog, also known as Numidargistat-analog and INCB01158-analog, is a potent and orally active arginase inhibitor with IC50=89 nM) . CB-1158 blocked myeloid cell-mediated suppression of T cell proliferation in vitro and reduced tumor growth in multiple mouse models of cancer, as a single agent and in combination with checkpoint blockade, adoptive T cell therapy, adoptive NK cell therapy, and the chemotherapy agent gemcitabine. CB-1158 increased tumor-infiltrating CD8+ T cells and NK cell...
T78053	PD-L1-IN-2	PD-1/PD-L1	Apoptosis; Cell Cycle/Checkpoint; Immunology/Inflammation
	"PD-L1-IN-2是一种具有潜力的肿瘤免疫治疗剂，具有抑制PD-L1的活性。该化合物为Naamidine J的衍生物，可通过降低体内PD-L1的表达并增强肿瘤浸润性T细胞的免疫反应来发挥抗肿瘤效果。PD-L1-IN-2主要应用于结直肠癌的研究领域。"